Skip to main content
. 2015 Dec 21;6:8995. doi: 10.1038/ncomms9995

Figure 7. Pharmacological MAP4K4 inhibition ameliorates atherosclerosis.

Figure 7

(a–c) ApoE−/− mice were administered PF-06260933 or vehicle twice daily for 6 weeks. (a) Dosing regimen (b) Oil red-O-stained en face aortic preparations from vehicle and PF-06260933-treated animals. (c) Quantification of the Oil Red-O-stained area. Data represent the mean±s.e.m. (*P<0.05, N=14–15). (d–f) Ldlr−/− mice were fed HFD for 10 weeks followed by PF-06260933 or vehicle administration daily for 10 additional weeks. (d) Dosing regimen. (e) Oil Red-O-stained en face aortic preparations from vehicle and PF-06260933-treated animals. (f) Quantification of the Oil Red-O-stained area. Data represent the mean±s.e.m. (**P<0.005, N=6).